ライフサイエンスコーパス: allergen-specific

1 Allergen-specific Ab responses were subsequently boosted

2 However, allergen-specific analyses suggested increased risks of

3 in infants at high risk of peanut allergy is allergen specific and does not prevent the development o

4 When used, allergen mitigation should be allergen specific and include multiple allergen-specific

5 No relevant change in allergen-specific and total IgE levels was observed in s

6 Atopy was determined based on allergen-specific and total IgE levels.

7 s was evaluated by immunoblotting using five allergen-specific antibodies and patients' serum followe

8 Almost all allergen-specific antibodies were mutated, and binding t

9 Allergen-specific antibodies were produced in rabbits us

10 ce-exposed but not shielded allergen induced allergen-specific antibodies, including IgE.

11 Allergen-specific antibodies, splenocyte cytokine produc

12 ted food allergies through the production of allergen-specific antibodies.

13 ion against allergen exposure in part due to allergen-specific antibodies.

14 Here, we investigated the association of allergen-specific antibody and T- as well as B-cell resp

15 fter 1 year of AIT, suggesting that dominant allergen-specific antibody clones remained as important

16 Allergen-specific antibody levels were measured in strep

17 296), the current study investigated the cat allergen-specific antibody responses.

18 The dissociation of allergen-specific antibody, and B- and T-cell responses

19 polyclonal IgG with CD64-IgE Fc established allergen-specific artificial sera that showed comparable

20 characterize the IgE sequences expressed by allergen-specific B cells and track the fate of these B-

21 vides the first detailed characterization of allergen-specific B cells before and after bee venom tol

22 Allergen-specific B cells in patients responding to AIT

23 epitope specificity, and clonal diversity of allergen-specific B cells in patients with food allergy

24 Long-term follow-up of allergen-specific B cells in terms of immunoglobulin iso

25 body IgE class switch recombination of food allergen-specific B cells occurs, and what processes are

26 rtoires identified additional members of the allergen-specific B-cell clones.

27 We sought to characterize peanut allergen-specific B-cell populations and the sequences a

28 Allergen-specific B-cell responses during 2 years of hou

29 Here, we defined the evolution of allergen-specific B-cell responses during epicutaneous s

30 t altering the capacity to induce functional allergen-specific blocking antibodies.

31 o induce a protective immunity consisting of allergen-specific blocking IgG antibodies and alteration

32 The induction of allergen-specific blocking IgG antibodies represents an

33 Here, we compared the induction of allergen-specific blocking IgG in outbred guinea pigs wh

34 enterotoxins promote TH2 differentiation of allergen-specific CD4 conventional T (Tcon) cells and as

35 model of airway inflammation, we found that allergen-specific CD4 T cells survived longer than 70 da

36 formed multimodal immunomonitoring to assess allergen-specific CD4 T-cell properties in parallel with

37 llergy interaction more fully, parasite- and allergen-specific CD4(+) T cell responses in 12 subjects

38 ed with clinical benefit than alterations of allergen-specific CD4(+) T-cell or IgG responses.

39 found that successful immunotherapy induces allergen-specific CD4+ T cells to expand and shift towar

40 Five of 57 allergen-specific cells belonged to clones containing Ig

41 Therefore, the assessment of allergen-specific cellular and humoral IgG1(+) immunity

42 Participants receiving placebo showed no allergen-specific changes.

43 The allergen-specific clones had increased persistence, high

44 eceptor (FcRN), and sensitized fetal MCs for allergen-specific degranulation.

45 Neutrophils can serve as APCs for local allergen-specific effector T cells in patients with alle

46 oped to enable the simultaneous detection of allergen-specific equine IgE in serum against a wide ran

47 Allergen-specific immunotherapy (AIT) is an allergen-specific form of treatment for patients sufferi

48 ization and disease progression; we analyzed allergen-specific germinal centers and IgG1(+) memory B

49 data provide a basis from which to evaluate allergen-specific human antibody repertoires in healthy

50 Support for the in vivo existence of allergen-specific human Breg cells comes from direct det

51 In vivo, allergen-specific human IgE level was strongly elevated

52 To mimic unspecific or allergen-specific ICs, plates were coated with myeloma I

53 ulating IgE(+) and IgG(+) memory B cells and allergen-specific Ig levels.

54 crude allergen from jellyfish and evaluated allergen specific IgE antibody levels using ELISA.

55 es showed higher levels of jellyfish-derived allergen specific IgE than healthy control samples.

56 xpansion of TH 2 cells and the production of allergen specific IgE.

57 years, and sensitization ever was defined as allergen-specific IgE >/=0.35 kUA /l to common food and/

58 was conducted using standard procedures and allergen-specific IgE (asIgE) using ImmunoCAP((R)) .

59 mination at age 2 years to assess eczema and allergen-specific IgE (sIgE) and perform skin prick test

60 tisation tested by skin prick test and serum allergen-specific IgE (sIgE) display nasal reactivity up

61 Serum total and allergen-specific IgE (sIgE) levels were measured by usi

62 gen specificity, 20% to 40% of children with allergen-specific IgE (sIgE) of 0.35 kU/L or greater had

63 a result of allergen proteins cross-linking allergen-specific IgE (sIgE) on the surface of mast cell

64 This fusion protein allowed the induction of allergen-specific IgE Ab responses without allergen-spec

65 complexes were formed with human monoclonal allergen-specific IgE and Bet v 1.

66 The variability in allergen-specific IgE and IgG frequencies depends on exp

67 Allergen-specific IgE and IgG to 156 allergens was measu

68 the simultaneous determination of total and allergen-specific IgE and IgG, antibodies using an immun

69 -MAPS) to the simultaneous detection of food allergen-specific IgE and IgG4 , and compared it with Im

70 h recombinant allergens, and measurements of allergen-specific IgE and IgG4 antibodies were performed

71 Allergen-specific IgE and IgG4 were detected in parallel

72 Methylation biomarkers outperformed allergen-specific IgE and skin prick tests for predictin

73 cted by a model that includes levels of free allergen-specific IgE and their interaction with blockin

74 re was a good correlation between the sum of allergen-specific IgE and total cockroach IgE levels (r

75 Allergen-specific IgE antibodies are a hallmark of type

76 generation of allergen-specific T cells and allergen-specific IgE antibodies.

77 efit of ImmunoCAP is the obtained quantified allergen-specific IgE antibody level and the lack of int

78 llergies, it is not understood why total and allergen-specific IgE concentrations do not reproducibly

79 Of 52 distinct allergen-specific IgE heavy chains from 8 allergic donor

80 have been successfully used for detection of allergen-specific IgE in patient sera.

81 izumab or placebo on the levels of total and allergen-specific IgE in patients with birch pollen alle

82 mented the short half-life of both total and allergen-specific IgE in serum.

83 The interaction of allergens and allergen-specific IgE initiates the allergic cascade aft

84 Allergen-specific IgE is the causative agent of allergic

85 the past 12 months, and at least 1 positive allergen-specific IgE level.

86 Allergen-specific IgE levels against seven common allerg

87 ells of allergic patients is correlated with allergen-specific IgE levels and determines allergen upt

88 For control purposes, total, allergen-specific IgE levels and omalizumab-IgE complexe

89 Overall 48.8% of the population had allergen-specific IgE levels of 0.3 ISAC standardized un

90 tion of more cockroach allergens with higher allergen-specific IgE levels was associated with disease

91 uantiBRITE beads and compared with total and allergen-specific IgE levels, as well as with allergen-i

92 administration of allergen induced rises of allergen-specific IgE levels, whereas intranasal adminis

93 omalizumab did not enhance systemic total or allergen-specific IgE levels.

94 7 serum mediators, total IgE levels, and 130 allergen-specific IgE levels.

95 ian's diagnosis and symptoms but no positive allergen-specific IgE levels.

96 Allergen-specific IgE measurements and the clinical hist

97 ts model, we determined risks of transfer of allergen-specific IgE or IgG responses 24 months post-tr

98 evels of Ara h 2 in circulation but not with allergen-specific IgE or mucosal mast cell protease 1 le

99 LA-specific IgE was not linked to atopy, and allergen-specific IgE present in allergic patients did n

100 Repeated allergen encounter boosts allergen-specific IgE production and enhances clinical s

101 Our data thus indicate that allergen-specific IgE production is boosted by allergen

102 -mediated food allergy through regulation of allergen-specific IgE production, FcepsilonR1-mediated M

103 at regulate the induction and maintenance of allergen-specific IgE production.

104 stem cell transplantation profoundly reduces allergen-specific IgE responses but also comes with a co

105 Analysis of allergen-specific IgE responses in birth cohorts with mi

106 IT over two weeks could sufficiently inhibit allergen-specific IgE responses in mice suffering OVA-in

107 Multiplex tests allow for measurement of allergen-specific IgE responses to multiple extracts and

108 undergoing stem cell transplantation, 94% of allergen-specific IgE responses were lost.

109 are involved in the immunological memory of allergen-specific IgE responses.

110 Examination of allergen-specific IgE revealed plasma IgE from DOCK8-def

111 Enrollment eczema and enrollment serum allergen-specific IgE sensitization to 1 or more foods (

112 (CRD) has become an accepted tool to detect allergen-specific IgE sensitization towards hundreds of

113 Allergen-specific IgE test (ImmunoCAP((R))) showed absol

114 lunch was examined using a prick-prick test, allergen-specific IgE test (ImmunoCAP((R))), and provoca

115 gnose the cause of the symptoms, a component allergen-specific IgE test after the identification of t

116 Because the allergen-specific IgE test is insufficient to diagnose t

117 Allergen-specific IgE tests (ImmunoCAP ((R))) showed pos

118 a cells (PCs) provide a continuous source of allergen-specific IgE that is central to allergic respon

119 Allergen-specific IgE titers and sensitization profiles

120 n prick test (SPT) and by the measurement of allergen-specific IgE to dust mites and cockroach in pla

121 Binding of allergen-specific IgE to its high-affinity receptor Fcep

122 create models for statistical integration of allergen-specific IgE to peanut/tree nut allergens from

123 d humans with IgE to allergens, but not when allergen-specific IgE was absent or only low-affinity.

124 Two years post-transplantation, recipients' allergen-specific IgE was significantly linked to the pr

125 ema, including filaggrin-null mutations, and allergen-specific IgE were more common among those with

126 tibody gene sequencing and identification of allergen-specific IgE with combinatorial antibody fragme

127 CD4 and CD8 T cells, eosinophils, total IgE, allergen-specific IgE, and urinary cotinine were measure

128 bodies against Streptococcus pneumoniae, and allergen-specific IgE, as well as detailed immunophenoty

129 d to the number of FcepsilonRI occupied with allergen-specific IgE, as well as the dose and valency o

130 based on the immunological determination of allergen-specific IgE, but the tests in the market lack

131 Total and allergen-specific IgE, IgG and basophil sensitivity were

132 This reduced GC responses, allergen-specific IgE, inflammation, pulmonary IL-13 and

133 lergen application induces rises of systemic allergen-specific IgE, we performed a double-blind place

134 Type I hypersensitivity is mediated by allergen-specific IgE, which sensitizes the high-affinit

135 Allergen-specific IgE-blocking IgG antibodies have been

136 rgic reaction, is dependent on high affinity allergen-specific IgE.

137 ith dysregulated type 2 immune responses and allergen-specific IgE.

138 l model for comparison to extract and marker allergen-specific IgE.

139 vation, and TH2 cytokine responses and serum allergen-specific IgE/IgG1 levels.

140 by intradermal testing or serum testing for allergen-specific IgE; crude extracts are the basis for

141 nts had positive test responses to 1 or more allergen-specific IgEs.

142 aeroallergen-specific IgE and corresponding allergen-specific IgG (sIgG) and associated immunophenot

143 in combination with LT from E. coli induced allergen-specific IgG antibodies blocking allergic patie

144 These findings suggest that allergen-specific IgG antibodies can act to induce and s

145 This may explain why naturally occurring allergen-specific IgG antibodies do not protect against

146 body level and the lack of interference from allergen-specific IgG antibodies.

147 solution data regarding early development of allergen-specific IgG are needed.

148 with the aim to investigate whether maternal allergen-specific IgG can protect against IgE sensitizat

149 Animal models have demonstrated that allergen-specific IgG confers sensitivity to systemic an

150 n at 5 years of age had significantly higher allergen-specific IgG levels than nonsensitized children

151 directed against peptide epitopes and higher allergen-specific IgG levels were found in HDM allergics

152 Maternal allergen-specific IgG persisted in some children at 6 mo

153 Children's allergen-specific IgG production occurred at 6 months an

154 High allergen-specific IgG reactivity in the mother's plasma

155 Allergen-specific IgG reactivity profiles in mothers, co

156 Allergen-specific IgG was administered to mice undergoin

157 lergen exposure, human IgE memory resides in allergen-specific IgG(+) memory B cells.

158 sed regulatory T-cell function and increased allergen-specific IgG(4) , yet little is known about the

159 ught to determine whether SCIT induces nasal allergen-specific IgG(4) antibodies with inhibitory acti

160 Allergen-specific IgG, which served as a surrogate marke

161 s by adaptive immune mechanisms that involve allergen-specific IgG1 antibodies and plasma or regulato

162 This process generated allergen-specific IgG1(+) germinal center B cells, serum

163 in from the egg white for sensitization, the allergen-specific IgG1(+) memory compartment predominant

164 ivity as well as a simultaneous detection of allergen-specific IgG4 , as a potential parameter for to

165 It is recommended to explore the use of allergen-specific IgG4 as a biomarker for compliance.

166 Detectable allergen-specific IgG4 could be determined only for low

167 unotherapy can stimulate somatic mutation of allergen-specific IgG4.

168 roup, P = .03) and a significant increase in allergen-specific IgG4.

169 h SCIT alone led to a sustained reduction in allergen-specific IL-4-producing cell counts (P < .01).

170 molecular compounds from pollen enhance the allergen specific immune response in the skin and nose.

171 In summary, we demonstrate non-allergen-specific immune network dysregulation in indivi

172 ted with characteristic modifications in the allergen-specific immune response, but a detailed synthe

173 lls can also contribute to the regulation of allergen-specific immune responses through other mechani

174 o comes with a considerable risk to transfer allergen-specific immune responses.

175 t of basophil sensitivity and an increase in allergen-specific immunoglobulin concentration.

176 ezing, skin prick test positivity (SPT), and allergen-specific immunoglobulin E (asIgE) after 3 years

177 fish and related allergens by skin prick and allergen-specific immunoglobulin E (IgE) (ImmunoCAP((R))

178 Hemisphere and is associated with increased allergen-specific immunoglobulin E (IgE) against a range

179 trate the detection of low concentrations of allergen-specific Immunoglobulin E (IgE) in human sera u

180 deterioration in asthma symptoms, change in allergen-specific immunoglobulin G4 (IgG4), change in as

181 9cRA signaling via RARalpha impacts the allergen-specific immunoglobulin response directly by th

182 Allergen specific immunotherapy has been shown to be the

183 icable, and easy to manufacture vaccines for allergen-specific immunotherapy (AIT) has been limited b

184 regulatory B (Breg) cell development during allergen-specific immunotherapy (AIT) has not been repor

185 Allergen-specific immunotherapy (AIT) induces specific b

186 Allergen-specific immunotherapy (AIT) is an allergen-spe

187 is is aimed mostly to relieve symptoms, only allergen-specific immunotherapy (AIT) is targeted to mod

188 Allergen-specific immunotherapy (AIT) is the only availa

189 Allergen-specific immunotherapy (AIT) is the only causal

190 ents from a double-blind, placebo-controlled allergen-specific immunotherapy (AIT) study indicated th

191 It is still unclear whether allergen-specific immunotherapy (AIT) with birch pollen

192 ted to mannan (PM) are suitable vaccines for allergen-specific immunotherapy (AIT).

193 PIT) is proposed as an alternative route for allergen-specific immunotherapy (AIT).

194 ion at a global, allergome-wide level during allergen-specific immunotherapy (AIT).

195 ggest for the use as adjuvant and carrier in allergen-specific immunotherapy (ASIT).

196 Recently, epicutaneous allergen-specific immunotherapy (EPIT) has proven effect

197 Epicutaneous allergen-specific immunotherapy (EPIT) is proposed as an

198 Sublingual allergen-specific immunotherapy (SLIT) intervention impr

199 tion with LT may be a promising strategy for allergen-specific immunotherapy against birch pollen all

200 Allergen-specific immunotherapy and biologic therapies t

201 lergic reactions are common in the course of allergen-specific immunotherapy and even occur with alle

202 However, subcutaneous allergen-specific immunotherapy can also induce anaphyla

203 To date, no safe allergen-specific immunotherapy for patients with peanut

204 common food hypersensitivities worldwide but allergen-specific immunotherapy for shellfish allergy is

205 Allergen-specific immunotherapy has shown promise for th

206 New strategies in allergen-specific immunotherapy have also emerged, such

207 chromatin landscape were observed following allergen-specific immunotherapy in cT(FH) and T(FR) cell

208 Allergen-specific immunotherapy is a disease-modifying t

209 Subcutaneous allergen-specific immunotherapy is a standard route for

210 Efficacy of allergen-specific immunotherapy is often severely impair

211 The goal of allergen-specific immunotherapy is the induction of prot

212 Allergen-specific immunotherapy is the only curative tre

213 Allergen-specific immunotherapy is the only known therap

214 Allergen-specific immunotherapy may be considered in cas

215 othesis-driven approaches as contributing to allergen-specific immunotherapy outcomes, but understand

216 ought to evaluate the efficacy and safety of allergen-specific immunotherapy using 2 dose regimens of

217 Allergen-specific immunotherapy via the skin targets a t

218 Allergen-specific immunotherapy with depigmented HDM ext

219 Allergen-specific immunotherapy with SHAS-OVA as compare

220 ction of their increase during the course of allergen-specific immunotherapy, as well as their increa

221 To address these limitations, adjunctive allergen-specific immunotherapy, vaccines, and non-aller

222 an be used to monitor the blocking effect of allergen-specific immunotherapy-induced non-IgE antibodi

223 fusion proteins can enhance the efficacy of allergen-specific immunotherapy.

224 lergic patients during the build-up phase of allergen-specific immunotherapy.

225 epresent promising vaccines for birch pollen allergen-specific immunotherapy.

226 r tailored management and the development of allergen-specific immunotherapy.

227 interaction have impaired the development of allergen-specific inhibitors of allergic responses.

228 Instead, lifelong reactivity is conferred by allergen-specific long-lived memory B cells that repleni

229 in the peripheral blood and stool mucus and allergen-specific lymphocyte stimulation test.

230 The 100-year-old personalized allergen-specific management of allergic diseases has pa

231 ponses to subsequent allergen exposure in an allergen-specific manner, effectively preventing or reve

232 the"LOW"responders, four cases showed >/=10% allergen-specific maximum histamine release.

233 tent allergen exposure, we hypothesized that allergen- specific memory Th2 cells are present and the

234 Altogether, we believe that allergen-specific memory T cells reside and function in

235 demonstrated a reduction in the frequency of allergen-specific (MHC II tetramer(+) ) CD4(+) T cells e

236 ld be allergen specific and include multiple allergen-specific mitigation strategies.

237 llergic sensitization, but whether these are allergen specific or increase susceptibility to poly-sen

238 omplex latent structure involving 7 age- and allergen-specific patterns in the COPSAC2000 birth cohor

239 In high-risk populations, allergen-specific prophylaxis could protect from sensiti

240 e aimed to investigate whether both types of allergen-specific reactivity can coexist in the same ind

241 es (IgG-IC) via breast milk and induction of allergen-specific regulatory T (T reg) cells in offsprin

242 panding populations of naturally suppressive allergen-specific regulatory T cells (Tregs).

243 nd Th2 differentiation, and the induction of allergen-specific regulatory T cells, highlighting its p

244 ethods, we demonstrated the ability to model allergen-specific relationships with acceptable measures

245 has valuable clinical implications for many allergen-specific responses and more broadly for any ant

246 ating the rate of transfer or maintenance of allergen-specific responses in the context of stem cell

247 ve data to estimate the risk of transmitting allergen-specific responses via hematopoietic stem cell

248 ogical mechanisms underlying the boosting of allergen-specific secondary IgE Ab responses and the all

249 Our results indicate that allergen-specific secondary IgE Ab responses can be boos

250 hich had been used for sensitization boosted allergen-specific secondary IgE responses without a dete

251 luded anaphylaxis scoring, quantification of allergen-specific serum IgE and IgG1 and of the mast cel

252 obe ameliorated asthma pathologies including allergen-specific serum IgE production, allergic lung an

253 Allergen-specific serum immunoglobulin E detection and q

254 Allergen-specific serum immunoglobulin E determination w

255 surements including positive SPT or elevated allergen-specific serum/plasma IgE levels.

256 sitive skin prick testing (SPT), or elevated allergen-specific serum/plasma immunoglobulin (Ig) E lev

257 This study presents a design of food allergen-specific sIgE inhibitors named covalent heterob

258 xposure, we assessed risk factors for atopy (allergen-specific skin prick test [SPT] reactivity and I

259 Recent studies have indicated that allergen-specific skin-resident memory T (T(RM)) cells p

260 epitope-derived peptide of Phl p 1 devoid of allergen-specific T cell epitopes, as recognized by BALB

261 oosted by repetitive B cell epitopes without allergen-specific T cell help by cross-linking of the B

262 f allergen-specific IgE Ab responses without allergen-specific T cell help.

263 secondary IgE responses without a detectable allergen-specific T cell response.

264 Neutrophils and allergen-specific T cells accumulate in patients with al

265 lymphocytes and results in the generation of allergen-specific T cells and allergen-specific IgE anti

266 SEA promoted TH2 responses of allergen-specific T cells and asthma pathogenesis by act

267 Transcriptomic analysis of allergen-specific T cells defined genes modulated in con

268 IgE complexes into B cells and activation of allergen-specific T cells depended on IgE binding to CD2

269 ced proliferation and cytokine production of allergen-specific T cells in vitro.

270 mportant role in controlling the activity of allergen-specific T cells through IgE-facilitated allerg

271 on by reducing the priming and activation of allergen-specific T cells, as well as the production of

272 unt of inhaled allergen is low, by expanding allergen-specific T cells.

273 C population, consistent with recruitment of allergen-specific T cells.

274 Circulating virus-specific T(H)1 cells and allergen-specific T(H)2 cells were precisely monitored b

275 virus-specific PD-1(+) T(H)1 cells, but not allergen-specific T(H)2 cells, were linked to worse lung

276 subjects versus controls, with synchronized allergen-specific T(H)2 expansion, and production of typ

277 c immunotherapy involves immunomodulation of allergen-specific T(H)2 responses and induction of IL-10

278 Allergen uptake and allergen-specific T-cell activation in relation to CD23

279 gE levels and influences allergen uptake and allergen-specific T-cell activation.

280 Allergen-specific T-cell proliferation and cytokine prod

281 ort of peanut-allergic participants, we used allergen-specific T-cell sorting and single-cell gene ex

282 The marked increase in APC function for allergen-specific TC proliferation during allergic infla

283 ) ) cells expressed more CD200R than the non-allergen-specific Th2 (CD154(-) CRTh2(+) ) cells.

284 e, both PLA2denat -MB formulations decreased allergen-specific Th2 CD4 T-cell reactivity.

285 Allergen-specific TH2 cells most closely paralleled the

286 Little is known about allergen-specific Th2 memory cells and their contributio

287 ligands IL-4 and IL-13 in the development of allergen-specific TH2 responses during the onset and chr

288 ver, mechanisms regulating acute and chronic allergen-specific TH2 responses in vivo remain incomplet

289 rmore, the development of disease as well as allergen-specific Th2 responses occurs despite deficienc

290 al (IN) nanoemulsion adjuvant that redirects allergen-specific Th2 responses toward Th1 and Th17 immu

291 en-specific immunotherapy, vaccines, and non-allergen-specific therapies (eg, monoclonal antibodies)

292 Beside avoidance, there is currently no allergen-specific therapy available.

293 of Immunity, Pepper and colleagues find that allergen-specific tissue-resident memory T cells are mai

294 er accounting for the ratio of component- or allergen-specific to total IgE can improve this predicti

295 The fraction of allergen-specific/total IgE may be useful to predict pat

296 potential of laser-facilitated epicutaneous allergen-specific treatment.

297 ributes to the allergic response by reducing allergen-specific Treg cell and activating mast cell cou

298 33-stimulated ILC2s blocks the generation of allergen-specific Treg cells and favors food allergy.

299 ke phenotype, also found in peripheral-blood allergen-specific Treg cells of food-allergic children.

300 By expanding allergen-specific Tregs and reducing pro-inflammatory ef